The United States Patent Trial and Appeal Board (PTAB) has denied biosimilar developer Samsung Bioepis’ request for inter partes review (IPR) of a patent that Genentech holds covering reference trastuzumab (Herceptin).
The United States Patent Trial and Appeal Board (PTAB) has denied biosimilar developer Samsung Bioepis’ request for inter partes review (IPR) of a patent that Genentech holds covering reference trastuzumab (Herceptin).
This is not the first time that the board has denied a claim for review of US Patent Number 7,846,441. Previously, Hospira, owned by Pfizer, and Celltrion had also petitioned PTAB to the Genentech patent in January 2017. Initially, the PTAB denied the review, but later reversed the decision after finding that Hospira had shown each of the patent’s claims were likely invalid.
Celltrion filed its own challenge in March 2017, in which PTAB had instituted an IPR, which Hospira subsequently joined.
Samsung Bioepis had stated that Genentech’s claim was obvious, based, in part, on a research paper. The same paper had been cited in both prior claims from Celltiron and Hospira.
In the board's denial of Samsung Bioepis’ request for an IPR proceeding, it explained that Samsung Bioepis’ evidence brought nothing new to the table. The research paper that had been cited in the 2 prior claims was cited in an additional reference provided by Samsung Bioepis, and that reference was cited by yet another. “In other words, Bioepis’ arguments on the newly asserted references are substantially the same as those in the earlier cases,” said the board.
According to Genentech, this particular paper was also considered in the prosecution of the patent. “Thus, after considering the totality of the circumstances, we agree with [Genentech] that it is appropriate for us to exercise our discretion to deny the petition under 35 USC § 325(d),” stated the board.
Although the outcome was favorable for Genentech, the pharma company is taking steps to further protect its drug from competitors and has recently indicated plans to seek injunctions to stop Samsung Bioepis from selling its biosimilar trastuzumab in Europe.
Genentech has requested US District Judge Robert Sweet to order Samsung Bioepis’ counsel, White & Case LLP, to share parts of its abbreviated Biologics License Application to examine certain chemical properties of the proposed trastuzumab biosimilar.
According to White & Case, Genentech is not entitled to receive this information from the European Medicines Agency and is “fishing” for grounds to challenge the biosimilar. The judge has yet to rule.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.